Fathy Fouad M, El-Kasah Fathi, El-Ahwal Abdulla M
Department of Parasitology, Faculty of Medicine, Alexandria University, Egypt.
J Egypt Soc Parasitol. 2009 Dec;39(3):881-905.
The present work aimed to determine the risk factors, lesion pattern and effective therapy of emerging ZCL in Sirte-Libya. The study was carried out on 163 patients referred to health centers of Al-Gadaheya and Al-Hisha villages in the years 2006 & 2007. Methods consisted of a predesigned questionnaire (personal and demographic data), clinical examination of lesions, and parasitological examination by slit smear, treatment and follow up. Results showed an annual incidence of 0.95%, with onset peak during autumn months. Important local risk factors included: increased occupational exposure of farmers and construction worker to infection from fat sand rat burrows, facilitated by lack of prevention knowledge and prophylactic measures; close association of bad-ventilated animal shelters to houses, and increased soil moisture by warm spring ponds. The majority of lesions were multiple (73%) located on legs, arms, and face 66.8%, 52.1% and 41.1%. Most lesions were active 1-2 month duration and 1-3 cm size, ulcerative type (77.3%), and papulo-nodular (21.5%). Giemsa slit smear proved quite reliable for active lesions, confirmed 79.5% of lesions. The majority of lesions (60.1%) were treated by intra-lesional Pentostam. Systemic route was restricted to facial, over-joint, multiple or large lesions producing, good response in 31.9%. Cryotherapy and oral Fluconazole gave satisfactory response in 5.5% & 2.5% of cases.
本研究旨在确定利比亚苏尔特新出现的皮肤利什曼病(ZCL)的危险因素、病变模式及有效治疗方法。该研究对2006年和2007年转诊至加达希亚和希沙村医疗中心的163例患者进行。方法包括预先设计的问卷(个人和人口统计学数据)、病变的临床检查、通过刮片进行的寄生虫学检查、治疗及随访。结果显示年发病率为0.95%,发病高峰在秋季。重要的局部危险因素包括:农民和建筑工人职业暴露于肥沙鼠洞穴感染的风险增加,缺乏预防知识和预防措施加剧了这种情况;通风不良的动物庇护所与房屋紧密相连,以及温暖的春季池塘使土壤湿度增加。大多数病变为多发(73%),位于腿部(66.8%)、手臂(52.1%)和面部(41.1%)。大多数病变活跃期为1 - 2个月,大小为1 - 3厘米,溃疡型(77.3%),丘疹结节型(21.5%)。吉姆萨刮片对活跃病变相当可靠,确诊了79.5%的病变。大多数病变(60.1%)采用病灶内注射喷他脒治疗。全身用药仅限于面部、关节周围、多发或大型病变,31.9%的患者反应良好。冷冻疗法和口服氟康唑在5.5%和2.5%的病例中反应良好。